SHORT-TERM TREATMENT FOR THE FULL SPECTRUM OF SAC SIGNS AND SYMPTOMS1-3 ALREX® (loteprednol etabonate ophthalmic suspension) 0.2% TREATS THE ITCH AND MORE1       A short-term course of ALREX® provides temporary multisymptom relief in SAC1-3       Itching Burning/ Stinging Discomfort Foreign-Body Sensation Tearing Redness       SAC=seasonal allergic conjunctivitis. Study design: Two 6-week, double-masked, placebo-controlled, multicenter environmental studies conducted during pollen season in which patients (N=268) with moderate to severe signs and symptoms of SAC bilaterally received ALREX® (0.2%) or placebo 4 times daily for 42 days. Primary efficacy variables were bulbar conjunctival injection (sign) and ocular itching (symptom) resolution at Day 14.2-3           CLICK HERE FOR YOUR COUPON OFFER           Indication and Usage     ALREX® (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.       Important Safety Information       •  ALREX is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of the ocular structures. ALREX is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.   • Prolonged use of ALREX is associated with several warnings and precautions, including glaucoma with optic nerve damage, defects in visual acuity, cataract formation, secondary ocular infections, exacerbation or prolongation of viral ocular infections (including herpes simplex), delay in wound healing and increase in bleb formation.   • If this product is used for 10 days or longer, intraocular pressure should be monitored. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after reexamination of the patient with the aid of magnification. Fungal infections of the cornea may develop with prolonged use of corticosteroids.   • Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2%-0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.       Click here for full Prescribing Information for ALREX.       References: 1. ALREX [package insert]. Tampa, FL: Bausch & Lomb Incorporated; 2013. 2. Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol. 1998;102(2):251-255. 3. Shulman DG, Lothringer LL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology. 1999;106(2):362-369.             For product-related questions and concerns, call 1-800-323-0000 or visit www.bausch.com.       ALREX is a registered trademark of Bausch & Lomb Incorporated or its affiliates. © Bausch & Lomb Incorporated. ALX.0099.USA.16     If you prefer not to receive e-mails from Bausch + Lomb, please use the following link to remove your e-mail address from this list: unsubscribe.